University Hospital Tuebingen
- Country
- 🇩🇪Germany
- Ownership
- Private
- Established
- 1388-01-01
- Employees
- -
- Market Cap
- -
Antibody CC-1 in Men With Biochemical Recurrence of Prostate Cancer
- Conditions
- Prostate Cancer Recurrent
- Interventions
- Drug: CC-1 Infusion
- First Posted Date
- 2022-12-12
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 56
- Registration Number
- NCT05646550
- Locations
- 🇩🇪
University Hospital Tuebingen, Tuebingen, Germany
Inflammation During ECMO Therapy and ECMO Weaning
- Conditions
- Acute Respiratory Distress Syndrome
- First Posted Date
- 2022-12-07
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 40
- Registration Number
- NCT05640635
- Locations
- 🇩🇪
University Hospital Tuebingen, Tuebingen, Baden-Wuerttemberg, Germany
Prospective Data Collection to Compare RAL for Hysterectomies and Other Indications in to Conventional Laparoscopy
- Conditions
- Uterine Diseases
- First Posted Date
- 2022-11-14
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 100
- Registration Number
- NCT05613816
- Locations
- 🇩🇪
University Hospital Tuebingen, Department of Women's Health, Tübingen, Germany
Brain-Oscillation-Synchronized Stimulation to Enhance Motor Recovery in Early Subacute Stroke
- Conditions
- Ischemic Stroke, Acute
- First Posted Date
- 2022-10-31
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 144
- Registration Number
- NCT05600374
- Locations
- 🇩🇪
Universitätsklinikum Frankfurt, Zentrum der Neurologie und Neurochirurgie, Frankfurt a.M., Germany
🇩🇪Universitätsmedizin Greifswald, Klinik und Poliklinik für Neurologie, Greifswald, Germany
🇩🇪Uniklinik Köln, Klinik und Poliklinik für Neurologie, Köln, Germany
DESENSITIZE-PD: Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Support Dopaminergic Desensitization in PD
- Conditions
- Parkinson Disease
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2022-10-18
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 20
- Registration Number
- NCT05579379
The Influence of Genetic Variations in ELAPOR1 or ELAPOR2 on Insulin Secretion and Glucose Regulation in Humans
- Conditions
- Impaired Insulin SecretionType 2 Diabetes
- First Posted Date
- 2022-10-12
- Last Posted Date
- 2023-09-25
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 20
- Registration Number
- NCT05575206
- Locations
- 🇩🇪
University Hopsital Tübingen, Tübingen, Germany
Remote Ischemic Preconditioning in Vestibular Schwannoma Surgery
- Conditions
- Vestibular Schwannoma
- First Posted Date
- 2022-10-05
- Last Posted Date
- 2022-10-05
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 120
- Registration Number
- NCT05567341
- Locations
- 🇩🇪
University Hospital Tuebingen, Tuebingen, Germany
Early Antibiotic Therapy and Vaccinations in Preterm Infants
- Conditions
- Vaccination Reaction
- Interventions
- Drug: ABT
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 82
- Registration Number
- NCT05563753
- Locations
- 🇩🇪
University Hospial Tübingen, Tübingen, Baden-Württemberg, Germany
The Effect of Two Different Non-pharmacologic Methods for Painandfear Relief During Blood Specimen Collection Inchildren
- Conditions
- Pain
- First Posted Date
- 2022-09-29
- Last Posted Date
- 2022-09-29
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 99
- Registration Number
- NCT05560074
- Locations
- 🇩🇪
University of Tübingen, Tübingen, Germany
Amantadine for Neuroenhancement in Acute Patients Study
- First Posted Date
- 2022-07-28
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 50
- Registration Number
- NCT05479032
- Locations
- 🇩🇪
Universitätsklinikum Tübingen, Tübingen, Germany